Background {#Sec1}
==========

Autosomal dominant polycystic kidney disease (ADPKD) is the commonest inherited kidney disease, with an estimated incidence of 1:400 to 1:1000; it accounts for 7--10% of all patients on renal replacement therapy worldwide \[[@CR1]\]. It is characterised by the development of renal cysts, hypertension, and extrarenal cysts, and results in end-stage renal disease (ESRD) \[[@CR2]\]. In addition, male patients with ADPKD usually show infertility resulting from cystic dilatation of the seminal vesicles \[[@CR3]\].

ADPKD is an autosomal dominant inherited disorder resulting from heterozygous mutations in three genes: *PKD1*, *PKD2,* and *GANAB*. Mutations of the first two genes (*PKD1* and *PKD2*) account for 80--85% and 15--20% of resolved cases, respectively \[[@CR4], [@CR5]\]. As of January 31, 2018, more than 2000 mutations (2323 in *PKD1* and 278 in *PKD2*) had been described in the Autosomal Dominant Polycystic Kidney Disease Mutation Database (PKDB; <http://pkdb.mayo.edu/>). Recently, two studies reported the association of the third ADPKD gene *GANAB*, or *PKD3* \[[@CR6], [@CR7]\], which accounts for \~ 0.3% of the total cases of ADPKD \[[@CR7]\].

In the present study, we performed mutational screening of *PKD1*, *PKD2,* and *GANAB* using long-range PCR (LR-PCR) and direct sequencing, as well as multiplex ligation-dependent probe amplification (MLPA) in 90 unrelated Chinese families with ADPKD. A total of 76 likely pathogenic or pathogenic mutations were identified in 77 families, including 38 novel mutations in PKD genes. These mutation data will contribute to improvement of diagnostics and genetic counselling in a clinical setting. In addition, this study highlights the correlation between men with ADPKD and infertility.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

A total of 90 unrelated families were recruited from the Reproductive and Genetic Hospital of CITIC-Xiangya in China from October 2012 to October 2017, including 72 patients with a positive family history of ADPKD. These patients either sought genetic counselling to avoid delivering a baby with ADPKD due to a positive family history, or sought treatment at our hospital for infertility and were diagnosed with ADPKD based on ultrasound examination before undergoing assisted reproductive technology treatment. All diagnoses were confirmed by ultrasound examination according to previously described criteria: (1) the presence of at least three (unilateral or bilateral) renal cysts in individuals aged 15 to 39 years, or (2) the presence of at least two cysts in each kidney in individuals aged 40 to 59 years, or (3) the presence of four or more cysts in each kidney in individuals aged 60 years and above \[[@CR8]\].

All individuals signed a written informed consent form, and blood samples were obtained from all probands and their family members when possible. The study was approved by the Ethics Committee of the Reproductive and Genetic Hospital of CITIC-Xiangya.

Semen analysis and assisted reproductive therapies {#Sec4}
--------------------------------------------------

Among the 90 unrelated ADPKD probands, 61 were male and 46 provided semen specimens for analysis. Specimens were collected by means of masturbation into a sterile container after 2--7 days of abstinence. All specimens were assessed according to the World Health Organization (WHO) 2010 recommendations \[[@CR9]\]. Briefly, within 1 h of ejaculation, the samples were liquefied and analysed for semen volume, sperm concentration, round cells, normal morphology, and sperm motility (defined as WHO motility grades A, B, C, and D, where grade A indicates fast progressive sperm; B, slow progressive sperm; C, nonprogressive sperm; and D, immotile sperm).

All patients providing semen specimens for analysis had a normal 46, XY karyotype, and no Y chromosome abnormalities were detected by microdeletion detection. Other causes of infertility, such as drugs and exposure to toxic substances, were excluded. Physical examination of these male patients showed normal results, including height, weight, hair distribution, mental state, and external genital organs.

Most of individuals who provided semen specimens for analysis have chosen different approaches to conceive offspring, including natural pregnancy, in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and ICSI combined preimplantation genetic diagnosis (PGD).

Mutation analysis of *PKD1*, *PKD2,* and *GANAB* {#Sec5}
------------------------------------------------

Genomic DNA (gDNA) was extracted from peripheral blood samples using a QIAamp® DNA blood midi kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. All patients were subjected to mutation screening of *PKD1* and *PKD2* using Sanger sequencing, followed by multiplex ligation-dependent probe amplification analysis (MLPA) to detect copy number variation in *PKD1* and *PKD2* in patients lacking definitely pathogenic point mutations in *PKD1* or *PKD2*. Subsequent screening of *GANAB* was carried out in patients for whom no causative genetic aetiology in *PKD1* and *PKD2* had been identified.

For exons 1--34 of *PKD1*, LR-PCR followed by nested PCR was performed with *PKD1*-specific primers, as previously described \[[@CR10]--[@CR12]\], and exons 35--46 of *PKD1* were directly amplified from gDNA by PCR. All exons of *PKD2* and *GANAB,* including the adjacent 30--60 bp intron sequence, were amplified from gDNA by PCR. The primers for amplification of *PKD1* were previously described, with minor modifications \[[@CR12], [@CR13]\]; specific primers for *PKD2* and *GANBA* were designed using Primer 3 online (<http://primer3.ut.ee>) according to reference sequences. The primers and conditions for PCR reactions are provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1, Additional file [2](#MOESM2){ref-type="media"}: Table S2, Additional file [3](#MOESM3){ref-type="media"}: Table S3, Additional file [4](#MOESM4){ref-type="media"}: Table S4. If a variant was identified as a putative disease-causative mutation, then mutation site screening of family members was implemented. DNA samples from all patients were screened by bidirectional sequencing on an Applied Biosystems 3130XL genetic analyser (Applied Biosystems, Foster City, CA, USA).

Copy number variation analysis of *PKD1* and *PKD2* was performed by MLPA with a SALSA MLPA probemix P351-C1/P352-D1 *PKD1-PKD2* kit (MRC-Holland, Amsterdam, the Netherlands) according to the manufacturer's instructions \[[@CR14]\]. This kit contains probes for 36 of the 46 exons of *PKD1* and 17 probes for *PKD2* exons, covering all PKD2 exons except exon 13 (two probes each for PKD2 exons 1, 2, and 6). The results of MLPA analysis were scanned on an Applied Biosystems 3130XL genetic analyser (Applied Biosystems, Foster City, CA, USA). The raw data were analysed using the Coffalyser MLPA analysis tool (MRC-Holland, Amsterdam, the Netherlands).

Evaluation of the pathogenicity of variations {#Sec6}
---------------------------------------------

The PKDB (<http://pkdb.mayo.edu>), the Human Gene Mutation Database (HGMD; <http://www.hgmd.cf.ac.uk/ac/index.php>), Exome Aggregation Consortium (EXAC; <http://exac.broadinstitute.org>), and the gnomAD database (<http://gnomad.broadinstitute.org>) were searched for previously reported variations. Frameshift variations, typical splicing, nonsense, and in-frame changes of two or more amino acids were defined as definitely pathogenic mutations \[[@CR2], [@CR15]\]. A novel mutation was defined as one that had not been described in PKDB or HGMD, or reported in ADPKD patients. The potential pathogenicity of all identified missense variants, indicated by a frequency below 1% in the Asian population of the Exac and gnomAD databases, was evaluated by pedigree analysis and in silico analysis using three different tools: SIFT (<http://sift.bii.a-star.edu.sg/>), Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2>), and MutationTaster (<http://www.mutationtaster.org/>). All variants were classified into five categories: 'pathogenic', 'likely pathogenic', 'uncertain significance', 'likely benign', and 'benign', according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines for the interpretation of variations \[[@CR16]\].

Results {#Sec7}
=======

Mutation analysis of *PKD1, PKD2,* and *GANAB* {#Sec8}
----------------------------------------------

We performed mutation screening of *PKD1*and *PKD2* for 90 probands using Sanger sequencing and MLPA. The 33 probands for whom no definitely pathogenic mutations were detected in *PKD*1 and *PKD2* were subjected to screening of *GANAB*. A total of 93 variations were identified in this study, comprising 84, 4, and 5 variations in *PKD1*, *PKD2,* and GANAB, respectively (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Among these variations, 51 are novel and have not been described in the ADPKD Mutation Database or HGMD, or been reported in ADPKD patients.Table 1Defnitely pathogenic mutations in PKD1 and PKD2 identified in this studycDNA changeExon/ intronAmino acid changeMutation TypeFamily No.Family historyKnown/Novel*PKD1* c.74dupG1p.Gly25Glyfs\*89Frameshift29YesNovel c.106_107insT1p.Pro36Leufs\*78Frameshift12YesNovel c.467_487del214p.Ala156_Ala162delIn-frame deletion49YesNovel c.856_862delTCTGGCC5p.Ser286Serfs\*2Frameshift30YesKnown c.1198C \> T5p.Arg400\*Nonsense17YesKnown c.1297C \> T6p.Gln433\*Nonsense48NAKnown c.2050A \> T10p.Arg684\*Nonsense47YesNovel c.2659delT11p.Trp887Glyfs\*11Frameshift50YesKnown c.2670 + 1G \> AIVS14-Splice19YesNovel c.4177C \> T15p.Gln1393\*Nonsense51YesNovel c.4447C \> T15p.Gln1483\*Nonsense13YesKnown14Yes c.4551C \> A15p.Tyr1517\*Nonsense39YesNovel c.4609G \> T15p.Glu1537\*Nonsense31YesKnown c.4846G \> T15p.Glu1616\*Nonsense37YesNovel c.4957C \> T15p.Gln1653\*Nonsense16YesKnown c.5014_5015delAG15p.Arg1672Glyfs\*98Frameshift53YesKnown c.5120G \> A15p.Trp1707\*Nonsense26YesKnown c.5637C \> G15p.Tyr1879\*Nonsense20YesNovel c.6115C \> T15p.Gln2039\*Nonsense55YesKnown c.6199C \> T15p.Gln2067\*Nonsense34YesKnown c.6804delG15p.Trp2268Cysfs\*46Frameshift63NoNovel c.6813_6814delAC15p.Arg2272Glyfs\*147Frameshift7YesKnown c.6945_6946insT16p.Gly2316Trpfs\*104Frameshift1YesNovel c.7126C \> T17p.Gln2376\*Nonsense45YesKnown c.7863 + 1G \> CIVS20-Splice36YesNovel c.7863 + 2 T \> GIVS20-Splice11YesNovel c.7915C \> T21p.Arg2639\*Nonsense54YesKnown c.7973_7974delTG21p.Val2658Glyfs\*2Frameshift9YesKnown c.8338G \> T23p.Glu2780\*Nonsense27YesKnown c.9666_9667delGA28p.Glu3222Aspfs\*30Frameshift32YesNovel c.10050 + 1G \> AIVS30-Splice44YesKnown c.10220 + 2 T \> CIVS32-Splice3YesKnown c.10397C \> G34p.Ser3466\*Nonsense6YesNovel c.10524_10525delAG35p.Glu3509Aspfs\*117Frameshift2NANovel c.10710_10715delGGCTGT36p.3571_3572del2In-frame deletion40YesKnown c.10724G \> A36p.Try3575\*Nonsense38NANovel c.10896_10897delGA37p.Ser3633Profs\*88Frameshift5NoNovel c.11240delC39p.Pro3747Hisfs\*79Frameshift33YesNovel c.11269 + 1G \> AIVS39-Splice10YesNovel c.11311_11312insGTGCT40p.Ser3771Cysfs\*57Frameshift41NANovel c.11512C \> T41p.Gln3838\*Nonsense15YesKnown c.11538-2A \> GIVS41-Splice18YesKnown c.11617_11637del2142p.3873_3879del7In-frame deletion4YesNovel c.11699_11700ins1042p.Leu3901Alafs\*63Frameshift22YesNovel c.11830_11838dup43p.Leu3944_Ala3946dupIn-frame duplication52YesNovel c.12101delT44p.Val4034Glyfs\*5Frameshift25NoNovel c.12139-2A \> TIVS44-Splice24YesNovel c.12391G \> T45p.Glu4131\*Nonsense43YesKnown c.12570_12571insCTCC46p.Ser4190Serfs\*21Frameshift28YesNovel c.12682C \> T46p.Arg4228\*Nonsense21YesKnown23Yes c.12712C \> T46p.Gln4238\*Nonsense46YesKnown EX31-33del31--33-Large deletion72NoNovel*PKD2* c.973C \> T4p.Arg325\*Nonsense8YesKnown c.1094 + 3_1094 + 6delAAGTIVS4-Splice35YesKnown c.2159dupA11p.Asn720Lysfs\*5Frameshift42YesKnown*NA* not available; \*translation termination codon. Novel mutation defined as one that had not been described in PKDB, HGMD, or reported in ADPKD patientsTable 2Evaluation of the pathogenic potential of PKD genes missense variantscDNA changeExonAmino acid changeCo-occurenceSIFTPolyPhen-2Mutation TasterFamily No.Family historySegregationKnown/NovelClassification*PKD1* c.1385G\>T6p.Arg462MetNTPRDD77YesYesNovelLP c.2039A \> T10p.Tyr680Phep.Tyr1879\*NTPODP20YesYesKnownLB c.2180 T\>C11p.Leu727ProNTPRDD69YesYesKnownLP c.2897G\>C12p.Arg966ProNTPRDD73YesYesNovelLP c.3548C \> G15p.Ser1183Trpp.Gln1653\*NTBP16YesYesNovelLB c.3613G\>C15p.Asp1205HisNTPODP64YesYesNovelLP76NoNA c.3868C \> G15p.Leu1290Valp.Gln1653\*TBP16YesYesNovelLB c.3931G\>A15p.Ala1311ThrNTBP80NoNoKnownLB c.4273C \> T15p.Arg1425Cysp.Gln3838\*NTBP15YesYesNovelLB c.5600A \> G15p.Asn1867Serp.Arg400\*NTPRDD17YesYesNovelUSV c.5957C\>T15p.Thr1986MetNTPRDP87YesNANovelLB c.6658C\>T15p.Arg2220TrpNTPRDD85YesYesKnownLP c.6704C\>T15p.Ser2235LeuNTPRDD70YesYesNovelLP c.6827 T\>C15p.Leu2276ProNTPRDD61YesYesKnownLP c.6878C \> T15p.Pro2293Leup.Pro36Leufs\*78NTPODP12YesNAKnownLB c.7099 T\>C17p.Ser2367ProNTPRDD56YesNANovelLP c.7144A\>C17p.Ser2382ArgNTPRDD67YesYesNovelLP c.7241C \> T18p.Thr2414Metc.11269 + 1G \> ANTPRDD10YesYesKnownLP c.7589G\>A19p.Gly2530AspNTPRDD59NoNAKnownLP c.8158A\>C22p.Thr2720ProNTPRDD86NANANovelLP c.8311G\>A23p.Glu2771LysNTPRDD83YesNAKnownLP c.8744A \> G23p.Asn2915Serp.Ser4190Serfs\*21TBD28YesYesNovelUSV c.8750C \> T23p.Ala2917Valp.Gln3838\*TPODP15YesYesKnownLBp.Gln1653\*16YesYes c.10937 T\>G37p.Val3646GlyTPRDD68YesYesNovelLP c.10951G\>A37p.Gly3651SerTPRDD79YesNAKnownLP c.11156G\>T38p.Arg3719LeuNTPRDD82YesYesNovelLP c.11248C\>G39p.Arg3750GlyNTPRDD74NoYesKnownLP c.11257C\>T39p.Arg3753TrpNTPRDD84YesYesKnownLP c.11351G \> T40p.Gly3784ValTBP75YesYesNovelLB c.11453G\>A41p.Gly3818AspNTPRDD81YesYesKnownLP c.11945A\>C43p.Gln3982ProNTPRDP78YesYesNovelLP c.12671C\>A46p.Thr4224AsnNTPODP66YesNANovelUSV*PKD2* c.965G\>A4p.Arg322GlnNTPRDD64YesNAKnownLP*GANAB* c.518G\>A5p.Arg173GlnTPRDD58YesNANovelB86NANA c.991C\>T10p.Arg331CysNTPRDD61YesNoNovelLB c.1078A\>G11p.Met360ValNTBD62YesNANovelUSV c.367C\>G4p.Pro123AlaTPODD69YesYesNovelUSV c.2292A\>G19p.Ile764MetTBDYesNovelUSV*NT* Not Tolerated, *T* Tolerated, *PRD* Probably damaging, *B* Benign, *POD* Possibly damaging, *D* Disease causing, *P* Polymorphism, *LB* likely benign variation, *LP* likely pathogenic variation, *USV* uncertain significance variation, *NA* not available, \*translation termination codon

Evaluation of the pathogenicity of variations {#Sec9}
---------------------------------------------

We evaluated the potential pathogenicity of all identified missense variants according to the ACMG standards and guidelines for the interpretation of variations. The results are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. A total of 84 variations were identified in *PKD1*, including 52 definitely pathogenic variations and 32 missense variants, 20 of which are classified as likely pathogenic mutations. Only four variants were identified in *PKD2*; three of them are definitely pathogenic mutations, and another is classified as likely to be pathogenic. Among the 76 definitely pathogenic or likely pathogenic mutations of *PKD1* and *PKD2*, 38 are novel. We identified five novel variations in *GANAB*. Two variations (p.Arg173Gln, and p.Arg331Cys) have been reported in the gnomAD database 431, and 1979 times, respectively, including 3, and 12 homozygotes, respectively, and are unlikely to be pathogenic. Three other variations (p.Pro123Ala, p.Met360Val, and p.Ile764Met) were identified in the gnomAD database 53,113, and 44 times, respectively, and are not very highly conserved. Two of these (p.Pro123Ala and p.Ile764Met) and a likely pathogenic mutation in PKD1 (p.Leu727Pro) were identified in family 69 with co-occurrence, and segregated with the disease in three affected family members. However, since functional analysis has not been performed, we are unable to determine their pathogenicity thus far, and they are classified as variants of uncertain significance.

Correlation with male infertility {#Sec10}
---------------------------------

In order to analyze the correlation between ADPKD mutations and male infertility, we analyzed the types of PKD genes mutations and semen quality. In our study, the analysis of semen from 46 male patients revealed that sperm from 37 individuals were abnormal; asthenozoospermia was detected in 18 individuals; 18 other individuals were affected with oligozoospermia or oligoasthenozoospermia; and 1 individual suffered from azoospermia. A total of 28 of the individuals with abnormal sperm were found to harbour definitely pathogenic mutations, and 7 individuals with normal sperm also carried definitely pathogenic mutations (Table [3](#Tab3){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). The results showed no correlation between semen quality and types of mutation in PKD genes.Table 3The semen analysis of 46 male patientsGenecDNA changeExon/ intronAmino acid changePredicted location within PKD1 domainsFamily No.Age^a^Inheriting/age^b^Semen analysisPKD1c.856_862delTCTGGCC5p.Ser286Serfs\*2Ig-like repeat domain3027maternaloligoasthenozoospermiaPKD1c.1385G\>T6p.Arg462MetC-type lectin domain7730paternal/25asthenozoospermiaPKD1c.2527 T \> C11p.Ser843Pronot defined4534paternal/22oligoasthenozoospermiaPKD1c.7126C \> T17p.Gln2376\*REJPKD1c.2670 + 1G \> AIVS14--Ig-like repeat domain1934maternalasthenozoospermiaPKD1c.3613G\>C15p.Asp1205HisIg-like repeat domain6430paternal/28asthenozoospermiaPKD2c.965G\>A4p.Arg322Gln--PKD1c.4447C \> T15p.Gln1483\*Ig-like repeat domain1330paternal/25oligoasthenozoospermiaPKD1c.4551C \> A15p.Tyr1517\*Ig-like repeat domain3931maternalasthenozoospermiaPKD1c.4609G \> T15p.Glu1537\*Ig-like repeat domain3137paternal/29asthenozoospermiaPKD1c.5957C\>T15p.Thr1986MetIg-like repeat domain8738paternal/23asthenozoospermiaPKD1c.6115C \> T15p.Gln2039\*Ig-like repeat domain5536paternal/25asthenozoospermiaPKD1c.6199C \> T15p.Gln2067\*Ig-like repeat domain3423maternaloligoasthenozoospermiaPKD1c.6658C\>T15p.Arg2220TrpREJ8531paternal/22oligoasthenozoospermiaPKD1c.6704C\>T15p.Ser2235LeuREJ7030paternal/29asthenozoospermiaPKD1c.7241C \> T18p.Thr2414MetREJ1030maternaloligoasthenozoospermiaPKD1c.11269 + 1G \> AIVS39--not definedPKD1c.7863 + 1G \> CIVS20--REJ3642maternaloligoasthenozoospermiaPKD1c.7863 + 2 T \> GIVS20--REJ1133maternalasthenozoospermiaPKD1c.7915C \> T21p.Arg2639\*REJ5435paternal/32asthenozoospermiaPKD1c.7973_7974delTG21p.Val2658Glyfs\*2REJ933paternal/28asthenozoospermiaPKD1c.8744A \> G23p.Asn2915Sernot defined2834maternaloligoasthenozoospermiaPKD1c.12570_12571insCTCC46p.Ser4190Serfs\*21not definedPKD1c.9666_9667delGA28p.Glu3222Aspfs\*30not defined3229paternal/24oligoasthenozoospermiaPKD1EX31-33del31--33--not defined7235de novooligozoospermiaPKD1c.10220 + 2 T \> CIVS32--not defined344NAoligoasthenozoospermiaPKD1c.12053C \> T44p.Thr4018Ilenot definedPKD1c.10397C \> G34p.Ser3466\*not defined627paternal/22oligoasthenozoospermiaPKD1c.10524_10525delAG35p.Glu3509Aspfs\*117not defined228NAoligoasthenozoospermiaPKD1c.6804delG15p.Trp2268Cysfs\*46REJ6335de novoazoospermiaPKD1c.10710_10715delGGCTGT36p.3571_3572del2Putative TM region4034maternalasthenozoospermiaPKD1c.10896_10897delGA37p.Ser3633Profs\*88not defined537de novooligoasthenozoospermiaPKD1c.10937 T\>G37p.Val3646Glynot defined6832paternal/26asthenozoospermiaPKD1c.10951G\>A37p.Gly3651Sernot defined7935maternaloligoasthenozoospermiaPKD1c.11240delC39p.Pro3747Hisfs\*79not defined3333paternal/25oligoasthenozoospermiaPKD1c.11538-2A \> GIVS41--not defined1836paternal/30oligoasthenozoospermiaPKD1c.11617_11637del2142p.3873_3879del7not defined425NAasthenozoospermiaPKD1c.11699_11700ins1042p.Leu3901Alafs\*63Putative TM region2229paternal/22asthenozoospermiaPKD1c.11830_11838dup43p.Leu3944_Ala3946dupPutative TM region5226paternal/21oligoasthenozoospermiaPKD1c.11945A\>C43p.Gln3982ProPutative TM region7833paternal/28asthenozoospermiaPKD1c.12712C \> T46p.Gln4238\*not defined4634maternalasthenozoospermiaPKD3c.518G\>A5p.Arg173Gln--5837paternal/27asthenozoospermiaPKD1c.1198C \> T5p.Arg400\*not defined1729maternalnormalPKD1c.5600A \> G15p.Asn1867SerIg-like repeat domainPKD1c.3931G\>A15p.Ala1311ThrIg-like repeat domain8027de novonormalPKD1c.2039A \> T10p.Tyr680Phenot defined2027paternal/27normalPKD1c.5637C \> G15p.Tyr1879\*Ig-like repeat domainPKD1c.4273C \> T15p.Arg1425CysIg-like repeat domain1531paternal/28normalPKD1c.8750C \> T23p.Ala2917Valnot definedPKD1c.11512C \> T41p.Gln3838\*Putative TM regionPKD1c.6813_6814delAC15p.Arg2272Glyfs\*147REJ732NAnormalPKD1c.7144A\>C17p.Ser2382ArgREJ6729maternalnormalPKD1c.10050 + 1G \> AIVS30--not defined4440paternal/30normalPKD1c.12139-2A \> TIVS44--Putative TM region2434maternalnormalPKD2c.2159dupA11p.Asn720Lysfs\*5--4229maternalnormal*REJ* receptor for egg jelly; *NA* not available; ^a^the age of the male patients seeking fertility advice from doctors; ^b^the age of the patients' fathers fathering their last child; \*translation termination codonFig. 1The semen quality of the male patients who harboured PKD1 mutations. DP, LP, LB and USV are indicated with definitely pathogenic mutations, likely pathogenic variations, likely benign variations and uncertain significance variations, respectively. The results showed that there is no correlation between semen quality and the type of mutation in *PKD1* gene

A total of 35 patients who provided semen specimens for analysis have chosen different approaches to conceive. Two patients (one with asthenozoospermia and the other with oligoasthenozoospermia) conceived naturally, and two individuals (one with asthenozoospermia and the other with normal sperm) conceived through ICSI. The 31 other patients chose ICSI combined with PGD; of these patients, genetic diagnosis of embryos has been completed for 22 and the treatment cycle is currently incomplete for 9 patients (Table [4](#Tab4){ref-type="table"}).Table 4The assisted reproductive therapies used by the 35 male patients and the clinical outcomes of those therapiesGenecDNA changeAmino acid changeFamily No.Semen analysisTreatment methodsPKD1c.856_862delTCTGGCCp.Ser286Serfs^\*^230oligoasthenozoospermiaICSI+PGDPKD1c.1385G\>Tp.Arg462Met77asthenozoospermiaICSI+PGDPKD1c.2527 T \> Cp.Ser843Pro45oligoasthenozoospermiaICSI+PGDPKD1c.7126C \> Tp.Gln2376^\*^PKD1c.2670 + 1G \> A--19asthenozoospermiaICSI+PGD^a^PKD1c.4447C \> Tp.Gln1483^\*^13oligoasthenozoospermiaICSI+PGD^a^PKD1c.4551C \> Ap.Tyr1517^\*^39asthenozoospermianatural pregnantPKD1c.4609G \> Tp.Glu1537^\*^31asthenozoospermiaICSI+PGDPKD1c.6199C \> Tp.Gln2067^\*^34oligoasthenozoospermianatural pregnantPKD1c.6658C\>Tp.Arg2220Trp85oligoasthenozoospermiaICSI+PGDPKD1c.6704C\>Tp.Ser2235Leu70asthenozoospermiaICSI+PGDPKD1c.7863 + 1G \> C--36oligoasthenozoospermiaICSI+PGDPKD1c.7863 + 2 T \> G--11asthenozoospermiaICSI+PGDPKD1c.10529C \> Tp.Thr3510MetPKD1c.7915C \> Tp.Arg2639^\*^54asthenozoospermiaICSI+PGDPKD1c.7973_7974delTGp.Val2658Glyfs^\*^29asthenozoospermiaICSIPKD1c.10529C \> Tp.Thr3510MetPKD1c.8744A \> Gp.Asn2915Ser28oligoasthenozoospermiaICSI+PGD^a^PKD1c.12570_12571insCTCCp.Ser4190Serfs^\*^21PKD1c.9666_9667delGAp.Glu3222Aspfs^\*^3032oligoasthenozoospermiaICSI+PGD^a^PKD1c.10220 + 2 T \> C--3oligoasthenozoospermiaICSI+PGD^a^PKD1c.12053C \> Tp.Thr4018IlePKD1c.10524_10525delAGp.Glu3509Aspfs\*1172oligoasthenozoospermiaICSI+PGDPKD1c.10896_10897delGAp.Ser3633Profs\*885oligoasthenozoospermiaICSI+PGD^a^PKD1c.10937 T\>Gp.Val3646Gly68asthenozoospermiaICSI+PGDPKD1c.11240delCp.Pro3747Hisfs^\*^7933oligoasthenozoospermiaICSI+PGD^a^PKD1c.11538-2A \> G--18oligoasthenozoospermiaICSI+PGDPKD1c.11699_11700ins10p.Leu3901Alafs^\*^6322asthenozoospermiaICSI+PGDPKD1c.11830_11838dupp.Leu3944_Ala3946dup52oligoasthenozoospermiaICSI+PGDPKD1c.11945A\>Cp.Gln3982Pro78asthenozoospermiaICSI+PGDPKD1c.12712C \> Tp.Gln4238^\*^46asthenozoospermiaICSI+PGDPKD1c.1198C \> Tp.Arg400^\*^17normalICSI+PGDPKD1c.5600A \> Gp.Asn1867SerPKD1c.3931G\>Ap.Ala1311Thr80normalICSIPKD1c.2039A \> Tp.Tyr680Phe20normalICSI+PGD^a^PKD1c.5637C \> Gp.Tyr1879^\*^PKD1c.4273C \> Tp.Arg1425Cys15normalICSI+PGD^a^PKD1c.8750C \> Tp.Ala2917ValPKD1c.11512C \> Tp.Gln3838^\*^PKD1c.6813_6814delACp.Arg2272Glyfs^\*^1477normalICSI+PGDPKD1c.7144A\>Cp.Ser2382Arg67normalICSI+PGDPKD1c.10050 + 1G \> A--44normalICSI+PGDPKD1c.12139-2A \> T--24normalICSI+PGDPKD2c.2159dupAp.Asn720Lysfs^\*^542normalICSI+PGD*ICSI* intracytoplasmic sperm injection, *ICSI+PGD* ICSI combined preimplantation genetic diagnosis, ^a^the treatment cycle is currently incomplete, \*translation termination codon

Discussion {#Sec11}
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In the present study, we analysed 90 unrelated patients affected with polycystic kidney disease, including 37 male patients with infertility. Screening of *PKD1*, *PKD2,* and *GANAB* was performed using a series of molecular genetic analyses. A total of 76 mutations (definitely or likely pathogenic mutations) were identified in 77 of the families, comprising 72 mutations in *PKD1* and 4 in *PKD2*. Pathogenic mutations in *GANAB* have never been identified in Chinese patients. To our knowledge, this is the first report of *GANAB* screening in a cohort of Chinese patients with ADPKD.

*PKD1*, *PKD2,* and *GANAB* are located in chromosome regions 16p13.3, 4q21--22, and 11q12.3, and they produce the proteins polycystin-1 (PC-1), PC-2, and neutral alpha-glucosidase AB, respectively \[[@CR17]\]. A series of molecular genetic analyses were used to screen for mutations of PKD genes. The human genome contains six truncated *PKD1* pseudogenes, which share approximately 97.7% similarity with exons 1--34 of *PKD1* \[[@CR18]\]. *PKD1* contains complex reiterated regions, necessitating that LR-PCR be performed prior to sequencing \[[@CR19]\]. Screening of *PKD2* was performed by direct Sanger sequencing. Subsequently, MLPA was employed to analyse the copy number variations of *PKD1* and *PKD2* in the genetically unresolved families, followed by screening of *GANAB* using direct Sanger sequencing. This strategy can typically identify almost all variants in PKD genes, as verified by our high mutation detection rate (85.6%,77/90). Recently, targeted next-generation sequencing and whole-exome sequencing have been used to identify mutations involved in ADPKD. Although these methods have high sensitivity, specificity, and accuracy, LR-PCR is still required; furthermore, highly specialised personnel and expensive equipment are required \[[@CR20]\]. Thus, the strategy for the identification of mutations in ADPKD used in the present study may be useful in a wide variety of situations.

A total of 2609 variants had been described before January 2018 (2323 in *PKD1*, 278 in *PKD2*, and 8 in *GANAB*). The majority of these variants were missense variants (1225). The others were protein-truncating variants (840), splice site mutations (165), in-frame indels (115), large deletions (24), and variations in the UTR and intervening sequences (228). In our study, a total of 76 mutations (definitely or likely pathogenic variations) were identified in 77 of the families, comprising 41 protein-truncating, 21 missense mutations, and 9 splice site mutations; 4 in-frame indels; and 1 large deletion variants. The positive detection rate was 85.6% (77/90), and 50% (38/76) of all mutations were novel. The proportion of patients with ADPKD with a family history of the disease accounted for 80% (72/90) of all probands, comparable to previously published data \[[@CR21]\].

A total of 76 mutations were identified, 72 of which (including 52 definitely pathogenic mutations) were in *PKD1,* accounting for 94.7%. Among all definitely pathogenic mutations of *PKD1*, 39 were truncating mutations, accounting for a large proportion (75%, 39/52), concordant with the results of other recent studies \[[@CR17]\]. Furthermore, one large deletion of *PKD1* was identified in our set of patients (1.1%, 1/90), in accordance with previously reported results \[[@CR22], [@CR23]\]. A total of 4 mutations were identified in *PKD2*, 3 of which were definitely pathogenic mutations. However, no hot-spots of mutation were identified in *PKD1* or *PKD2*, indicating that for identification of future mutations, all exons of *PKD1* and *PKD2*, including their intron-exon boundaries, should be sequenced.

*GANAB* has been implicated in the development of autosomal-dominant polycystic kidney and liver disease \[[@CR7]\]. In this study, a total of five mutations with a frequency below 1% were identified in the Asian population of the Exac and gnomAD databases; all are missense mutations. Only two mutations (p.Pro123Ala and p.Ile764Met) co-occurred in family 69; these have been described a few times and were found to have segregated with the disease in affected family members, accounting for 1.1%. The patients in this family all suffered from polycystic kidney with liver disease, consistent with earlier findings that the phenotype caused by *GANAB* mutations usually manifests with polycystic liver disease (PLD) \[[@CR7]\]. In addition, the patients from family 69 also carried the p.Leu727Pro mutation in *PKD1*, which has been reported in several families and classified as a highly likely pathogenic mutation \[[@CR17], [@CR24]\]. As p.Pro123Ala was predicted to be a disease-causing mutation by three tools and p.Ile764Met was predicted to be benign by PolyPhen-2, the possibility that p.Leu727Pro in *PKD1* and p.Pro123Ala in *GANAB* co-contribute to the development of polycystic kidney with liver disease cannot be excluded. Thus, the fact that no definitely or likely pathogenic mutation was detected in this study suggested that GANAB mutations are rare in Chinese patients with ADPKD.

Earlier studies have reported that *HNF1B* can phenocopy ADPKD \[[@CR25]--[@CR27]\]. In addition, it has been very recently reported that monoallelic mutation in *DNAJB11* can cause atypical ADPKD, which is a phenotypic hybrid of ADPKD and autosomal-dominant tubulointerstitial diseases (ADTKD) \[[@CR28]\]. In our study, for the 13 patients with or without a positive family history, the genetic cause remains unknown, but undetected *PKD1*, *PKD2,* or *GANAB* mutations, including deep intronic or synonymous exonic mutations that cause atypical splicing, or large deletions of *GANAB*, could be the underlying reasons. Furthermore, the patients should be reevaluated based on their most recent phenotype, and should be screened for other genes implicated in ADPKD for future analysis, such as *HNF1B* and *DNAJB11*.

ADPKD is a systemic disorder and extrarenal manifestation is not uncommon. Male patients with ADPKD usually suffer from infertility, resulting from abnormal semen, including necrospermia, immotile sperm, asthenozoospermia, and azoospermia \[[@CR29]--[@CR31]\]. PKD1 and PKD2 have been reported to play a pivotal role in the development and maintenance of the male reproductive tract \[[@CR32], [@CR33]\]. The potential aetiologies of semen abnormalities in male patients with ADPKD include ejaculatory duct cysts, seminal vesicle cysts, and ultrastructural flagellar defects caused by abnormal polycystins \[[@CR30]\]. However, the correlation between the type of PKD gene mutation and semen quality remains unclear. In the present study, 37 individuals were found to have abnormal semen (80%, 37/46). Only some of the male patients with ADPKD carrying definitely pathogenic mutations were infertile, which may indicate that there is no correlation between the type of PKD1 mutation and semen quality. However, 23 of the variations are located in the same four domains of *PKD1*, and more than one third of the mutations (39%,9/23) are located in the Ig-like repeat domain, which is a conserved region of approximately 85 bp surrounding a central sequence consisting of 16 copies \[[@CR34]\]. Defects of the Ig-like repeat domain in PKD1 protein may alter its binding ability, leading to male reproductive tract cysts and infertility \[[@CR34]\]. Thus, male patients carrying pathogenic mutations in *PKD1* located in the Ig-like repeat domain may have a high risk of infertility. In addition, 20 and 3 of the mutations identified in the 23 male patients with ADPKD with abnormal semen were paternal and de novo, respectively. However, almost all of these fathers fathered their children when they were younger than the age at which their sons with ADPKD sought fertility advice from their doctors. Furthermore, after the treatment of ICSI, 17 individuals affected with semen abnormalities all achieved paternity or at least obtained embryos. Therefore, we suggest that male patients with ADPKD should achieve paternity as young as possible, and the use of ICSI combined PGD should be considered for patients suffering from low semen quality \[[@CR30], [@CR31]\].

In this study, the majority of male patients with ADPKD were found to have abnormal semen (80%), which could due to a selection bias in the study population. Since our hospital specializes in reproductive and genetic disorders, most of the subjects included in the study visited our hospital to seek treatment for infertility. Thus, the proportion of males with abnormal sperm quality is not a true reflection of the proportion of male ADPKD patients with abnormal sperm. Therefore, studies on larger groups of patients with ADPKD recruited from general hospitals are needed to obtain a more accurate estimation of the proportion of ADPKD-affected males with abnormal sperm.

Conclusions {#Sec12}
===========

In conclusion, we identified a group of novel mutations in PKD genes, which enriches the PKD mutation spectrum. Male patients with ADPKD are usually affected with infertility, and surgical sperm retrieval combined with assisted reproductive technology may help them to achieve paternity. Our study will provide clinicians with precise diagnoses that have implications for family planning and genetic counselling of affected individuals.

Additional files
================

 {#Sec13}

Additional file 1:**Table S1.** Primers used in long-range PCR of *PKD1* homologous regions. (DOC 37 kb) Additional file 2:**Table S2.** Primers used in nested PCR of *PKD1* homologous regions. (DOC 78 kb) Additional file 3:**Table S3.** Primers used in PCR of *PKD1* single-copy regions. (DOC 40 kb) Additional file 4:**Table S4.** Primers used in PCR of *PKD2* and *GANAB*. (DOC 53 kb)

ACMG

:   American College of Medical Genetics and Genomics

ADPKD

:   Autosomal dominant polycystic kidney disease

ESRD

:   End-stage renal disease

HGMD

:   Human gene mutation database

ICSI

:   Intracytoplasmic sperm injection

LR-PCR

:   Long-range PCR

MLPA

:   Multiplex ligation-dependent probe amplification

PC-1

:   Produce the proteins polycystin-1

PC-2

:   Produce the proteins polycystin-2

PKDB

:   Autosomal dominant polycystic kidney disease mutation database

PLD

:   Polycystic liver disease

WHO

:   World Health Organization

We would like to thank the patients and their family members for their support and participation in this research. We would also like to thank the genetic counselling team at the Reproductive and Genetic Hospital of CITIC-Xiangya and the clinicians who referred the patients for the clinical study.

Author' contributions {#FPar1}
=====================

JD designed the study. WBH, WJX, XMZ, QJZ, and WL performed the mutation analysis of *PKD1*, *PKD2*, and *GANAB.* JD and WBH carried out the evaluation of the pathogenicity of variations. CGZ, XRL, LH, GXL, and GL worked on the clinical study. WBH, WJX and YQT wrote the paper. All authors read and approved the final manuscript.

Funding {#FPar2}
=======

This study was supported by grants from the National Natural Science Foundation of China (81771645 and 81471432), Scientific Research Foundation of Reproductive and Genetic Hospital of CITIC-Xiangya (YNXM-201802) and Graduate Research and Innovation Projects of Central South University (Grant 2017zzts372).

Availability of data and materials {#FPar3}
==================================

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate {#FPar4}
==========================================

Approval of this study was obtained from Reproductive and Genetic Hospital of CITIC-Xiangya. Written informed consent for analyses was obtained from all participants.

Consent for publication {#FPar5}
=======================

No individual patient data has been reported in the current study and consent for publication is not applicable.

Competing interests {#FPar6}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
